Microalgal extract from thermotolerant Coelastrella sp. F50 retards the liver tumor progression by targeting hepatic cancer stem cells

Yi‐Chen Chang,Tian‐Huei Chu,Po‐Chien Yu,E‐Ming Wang,Chao‐Cheng Huang,Tsung‐Hui Hu,Zhi‐Hong Wen,Chou‐Yuan Ko,Ching‐Nen Nathan Chen,Ming‐Hong Tai
DOI: https://doi.org/10.1002/ptr.7111
IF: 6.388
2021-04-07
Phytotherapy Research
Abstract:<p>Microalgae extracts have shown antitumor activities. However, the antitumor mechanism of them is not yet completely clear, especially the effect on cancer stem cells (CSCs). This study aimed to elucidate the antitumor activity and mechanism of microalgal extract from thermotolerant <i>Coelastrella</i> sp. F50 (F50) in hepatocellular carcinoma (HCC). Oncogenic behaviors were analyzed using cell proliferation, colony formation, invasion, sphere formation, and side population cells (SPCs) assays in HCC cells after F50 treatment. The molecular mechanism was further studied by quantitative real‐time PCR, immunoblot, and immunofluorescence analyses. The chemopreventive efficacy of F50 was evaluated in rat orthotopic hepatoma, and the hepatic pathologies were investigated by immunohistochemical, immunoblot, and immunofluorescence analyses. F50 specifically suppressed hepatic CSCs (tumor spheres, drug efflux, CD133/ABCG2 CSCs markers) with no cytotoxicity <i>in vitro</i>. In the animal experiments, prophylactic F50 administration significantly attenuated tumor progression and improved liver function in HCC‐bearing rats. In the mechanistic analysis, F50 potentially inhibited cyclooxygenase‐2 (COX‐2)/prostaglandin E2 (PGE<sub>2</sub>) axis in HCC cells and rat hepatoma, and exogenous PGE<sub>2</sub> restored CSCs properties in F50‐treated HCC cells. In summary, F50 extract inhibits hepatic CSCs by COX‐2/PGE<sub>2</sub> downregulation and may facilitate a novel phytotherapy for HCC prevention.</p>
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?